Nektar Therapeutics (NKTR) Assets Average (2011 - 2026)

Nektar Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $521.8 million for Q1 2026.

• In Q1 2026, Assets Average rose 86.34% year-over-year to $521.8 million; the TTM figure through Mar 2026 stood at $521.8 million (up 86.34% YoY), while the FY2025 annual figure was $292.1 million, down 16.76% from the prior year.
• Assets Average was $521.8 million for Q1 2026 at Nektar Therapeutics, up from $290.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.1 billion in Q1 2022 to a low of $231.9 million in Q2 2025.
• Historically, Assets Average has averaged $506.5 million across 5 years, with a median of $420.1 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Assets Average slumped 44.01% in 2023, then soared 86.34% in 2026.
• A 5-year view of Assets Average shows it stood at $745.8 million in 2022, then tumbled by 43.67% to $420.1 million in 2023, then fell by 27.19% to $305.9 million in 2024, then dropped by 4.91% to $290.9 million in 2025, then jumped by 79.4% to $521.8 million in 2026.
• The last three Assets Average figures came in at $521.8 million (Q1 2026), $290.9 million (Q4 2025), and $254.4 million (Q3 2025), per Business Quant data.